Mereo reports Phase II data for COPD candidate acumapimod

By Elizabeth S. Eaton | Jan 5, 2018 | 10:21 PM GMT

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase II trial in 282 patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) showing that low- and high-dose acumapimod